

Correction

Correction: Effects of the proteasome inhibitor PS-341 on apoptosis and angiogenesis in orthotopic human pancreatic tumor xenografts

In this article (*Mol Cancer Ther* 2002 1(14):1243-53), published in the December 1, 2002 issue of *Molecular Cancer Therapeutics* (1), the same images were used to represent multiple treatment conditions in Fig. 4A and B:

(1) The same image was used to represent treatment of L3.6pl (Fig. 4A) and Mia PaCa-2 (Fig. 4B) with 0.6 mg/kg PS-341 as well as treatment of Mia PaCa-2 with





Figure 4.

0.8 mg/kg PS-341 (Fig. 4B).

(2) The same image was used to represent treatment of L3.6pl (Fig. 4A) and Mia PaCa-2 (Fig. 4B) with 1.0 mg/kg PS-341.

(3) The same image was used to represent drug control in L3.6pl (Fig. 4A) and Mia PaCa-2 (Fig. 4B).

The authors have corrected the figures and regret their errors. The corrected version is displayed on the previous page.

Corrections for several other articles published in AACR journals containing similar errors have been published. The original articles and their corrections are:

Nawrocki ST, Carew JS, Pino MS, Highshaw RA, Dunner K, Jr., Huang P, Abbruzzese JL, McConkey DJ. Bortezomib sensitizes pancreatic cancer cells to endoplasmic reticulum stress-mediated apoptosis. *Cancer Res* 2005;65:11658-66. doi: 10.1158/0008-5472.CAN-05-2370.

Correction in: *Cancer Res* 2009;69:1695. Published OnlineFirst February 10, 2009. doi: 10.1158/0008-5472.CAN-69-4-COR1.

Pino MS, Shrader M, Baker CH, Cognetti F, Xiong HQ, Abbruzzese JL, McConkey DJ. Transforming growth factor alpha expression drives constitutive epidermal growth factor receptor pathway activation and sensitivity to gefitinib (Iressa) in human pancreatic cancer cell lines. *Cancer Res* 2006;66:3802-12. doi: 10.1158/0008-5472.CAN-05-3753.

Correction In: *Cancer Res* 2009;70. Published OnlineFirst December 1, 2009. doi: 10.1158/0008-5472.CAN-09-4221.

Nawrocki ST, Sweeney-Gotsch B, Takamori R, McConkey DJ. The proteasome inhibitor bortezomib enhances the activity of docetaxel in orthotopic human pancreatic tumor xenografts. *Mol Cancer Ther* 2004;3:59-70.

Correction in: *Mol Cancer Ther* 2009;8:479. Published OnlineFirst February 3, 2009. doi: 10.1158/1535-7163.MCT-08-2-COR1.

Papageorgiou A, Kamat A, Benedict WF, Dinney C, McConkey DJ. Combination therapy with IFN-alpha plus bortezomib induces apoptosis and inhibits angiogenesis in human bladder cancer cells. *Mol Cancer Ther* 2006;5:3032-41. doi:10.1158/1535-7163.MCT-05-0474.

Correction In: *Mol Cancer Ther* 2009;8:480. Published OnlineFirst February 3, 2009. doi: 10.1158/1535-7163.MCT-08-2-COR2.

The errors in the aforementioned articles were caused in large part by inadequate oversight of data management. In an effort to prevent such errors from occurring in the future, the PI (DJM) has implemented a new data management policy that is designed to limit or eliminate errors in future publications and can be provided upon request (dmconcke@mdanderson.org). The authors note that the conclusions and interpretation of the data in these articles are unaltered by the errors that are now corrected.

Reference

1. Nawrocki ST, Bruns CJ, Harbison MT, Bold RJ, Gotsch BS, Abbruzzese JL, Elliott P, Adams J, McConkey DJ. Effects of the proteasome inhibitor PS-341 on apoptosis and angiogenesis in orthotopic human pancreatic tumor xenografts. *Mol Cancer Ther* 2002;1:1243-53.